- Sustainability
- DE&I
- Pandemic
- Finance
- Legal
- Technology
- Regulatory
- Global
- Pricing
- Strategy
- R&D/Clinical Trials
- Opinion
- Executive Roundtable
- Sales & Marketing
- Executive Profiles
- Leadership
- Market Access
- Patient Engagement
- Supply Chain
- Industry Trends
Europe and Canada Welcome Trade Agreement Text
The European Federation of Pharmaceutical Industries and Associations (EFPIA) and Canada’s Research-Based Pharmaceutical Companies (Rx&D) have welcome finalization of the text for the Comprehensive Economic and Trade Agreement (CETA).
The European Federation of Pharmaceutical Industries and Associations (EFPIA) and Canada’s Research-Based Pharmaceutical Companies (Rx&D) have welcome finalization of the text for the Comprehensive Economic and Trade Agreement (CETA).
CETA represents the first free trade agreement between any G8 country. EFPIA and Rx&D believe it will, once in place, be beneficial to patients on both sides of the Atlantic, as well as for innovation and research.
Russell Williams, President, Rx&D: “CETA represents an important step towards putting Canada on the same playing field as its major trading partners… We now look to the governments involved to move swiftly on implementation; this is good for all the countries involved, and it’s good for Canadians.”
Click here for Pharm Exec columnist Tom Norton’s take on the Canadian–European agreement.
Fierce Females in the Life Science Space
March 29th 2024In this week’s episode, in recognition of international women’s month, Editor Miranda Schmalfuhs has compiled audio clips from interviews with female KOLs that she's been fortunate enough to speak with over this past month for content across a few of our brands.
